Efficacy of a novel anti-IL-1B receptor modulator in reducing preterm birth impact on neurovascular health

Preterm neonates ill-adapted to the extra uterine environment are prone to increased inflammation in multiple organs and the proinflammatory interleukine IL-1b has been closely implicated in brain injury associated with preterm birth (PTB). One major adverse neuronal outcome for PTB survivors is the greater propensity to develop ischemic brain lesions long after birth. Here, we hypothesize that the neural vasculature of premature infants becomes maladapted to appropriately respond to hypoxic-ischemic stress.

Identification of medical marijuana cultivars with great potential for therapeutic application

The proposed project will use classical animal models to investigate the therapeutic effects and associated side effects of extracts from the whole plant of different strains of cannabis. The targeted medical conditions include pain and chemotherapy induced nausea and vomiting (CINV). Our data and results will play a key role in pre-screening of cultivars to obtain best candidates suited for particular medical conditions, or that have lower side-effect liability.

Implementation of an adventitious agent assay by HTS

Manufacturing of consistently high quality products is the commitment of the pharmaceutical industry. To achieve this, new products must be thoroughly tested and the results must meet government-approved product specifications. Improving existing and adopting improved analytical technologies for product testing ensure the production of safe and effective products. This is particularly critical for the manufacturing of vaccines and biologics which, relative to small molecular drugs, are more susceptible to contamination by viral or microbial adventitious agents.

Assessing the Bioactivity of Leech Saliva Extract (LSE) in Combination with Conventional Pharmacological Treatment in Vitro and in Vivo

Medical leeching can be traced back to the beginning of civilization. Ancient Egyptians, Indians, and Greek physicians used leeching as a treatment for a variety of diseases. In the past few decades, comprehensive studies have investigated the therapeutic applications of leech products and especially leech saliva. Recent studies completed by our lab have determined a therapeutic potential of a leech saliva extract component (BPS-001), with demonstrated strong anticancer properties.

Novel formulation for the treatment of interstitial cystitis

Interstitial cystitis is an inflammatory disease of the urinary bladder and is recognized as a serious medical condition associated with a profoundly negative impact on patients’ quality of life. Currently, there are no widely acknowledged causes of this disorder and no effective treatments available. Panag is a Halifax based drug company which focuses on development of novel therapeutic treatments which can be used to alleviate both pain and inflammation associated with IC. The goal of our research is to provide IC patients with symptom and pain relief, as well as to improve outcome.

A Computational Modelling Framework for Evaluation of Pandemic Vaccine Strategies

Medicago, a clinical-stage biopharmaceutical company, has the potential to rapidly develop a vaccine in response to a newly sequenced influenza strain, allowing for large-scale vaccination of the population very early during a pandemic. The company would like to know how many doses of vaccine is required and what distribution strategies should be used to maximize population-wide benefits of vaccination in the event of an influenza pandemic.

Formulation and Toxicology of Bone-Targeting Nanoparticles - Year two

Bones undergo a renewal process by replenishing calcium mineral through a cellular process known as remodeling. Usually, it happens in a balanced manner, but in many bone diseases, the remodeling process is increased with regional bone metabolism. Bisphosphonate (BP) drugs selectivity and strongly bind to bone mineral and become incorporated at active sites of bone turnover in an increased amount.


Drug-induced dyskinesia is a debilitating side effect induced by anti-parkinsonian and antipsychotic drugs. Frequency can reach 80% in Parkinson’ disease and around 50% in schizophrenia patients treated with typical antipsychotics. Treatments for dyskinesia currently available have a very limited impact and generate important side effects. We have identified a new pharmacological target that may offer a new perspective in the treatment of these conditions. The target is composed of two nuclear receptors involved in the modulation of gene expression.

Using Deep Convolutional Neural Networks to predict compound-target interactions

Getting a new drug from the laboratory into the market is a lengthy and costly process which takes on average 12 years and over US$350 million to accomplish. It is composed of roughly 3 phases: (1) pre-clinical research, (2) clinical studies, and (3) the new drug application review. In this work, we propose an artificial intelligence system which will shorten the time it takes for pharmaceutical companies to identify novel drugs (compounds) for a given target (usually a protein or a protein complex).

Freeze-drying of antibiotic vials: monitoring and optimizing process trajectories on an industrial scale

There has been an increased use of freeze-drying in the pharmaceutical industry over the past few decades. This step converts a liquid product into a solid one without compromising its integrity, thus prolonging its shelf life. The monitoring and optimization of this process is commonly done by trial-and-error, leading to product quality control issues. Therefore, the implementation of new monitoring tools in this process could allow a better understanding and control.